Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Cetuximab by Eli Lilly and Co for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
Cetuximab is under clinical development by Eli Lilly and Co and currently in Phase II for Cutaneous Squamous Cell Carcinoma...
Data Insights
Cetuximab by Eli Lilly and Co for Anal Cancer: Likelihood of Approval
Cetuximab is under clinical development by Eli Lilly and Co and currently in Phase II for Anal Cancer. According to...